

Dermatological Treatments

Reference Number: RDF2164-23

Date of Response: 27/12/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions.

Q1. How many patients were treated in the last 4 months (August to November 2023) by the dermatology department with each of the following products:

Answer: Please see table below:

Drug	Total patients
Abrocitinib	8
Acitretin	131
Alitretinoin	20
Azathioprine	0
Baricitinib	*<5
Ciclosporin	18
Dupilumab	172
Methotrexate	245
Mycophenolate mofetil	14
Pimecrolimus	16
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	*<5
Tacrolimus ointment	76
Tralokinumab	11
Upadacitinib	10

Q2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

Answer: Please see table below:

Age	Total patients
Age 6-11	21
Age 12-17	15
Age 18 and above	682

Please note: * <5 Section 40 (2) - question 1:

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.